TNFR2-R 功能获得性变异与银屑病关节炎抗 TNFα 治疗应答不足相关
本研究纳入 164 例银屑病关节炎患者,评估 TNFR2 rs1061622 多态性(TNFR2-M 或 TNFR2-R)与 TNFi 治疗应答的关联,主要结局为因疗效不足在 12 个月内停用 TNFi。携带 TNFR2-R 变异的患者停用 TNFi 的可能性约为 TNFR2-M 携带者的 5 倍(95% CI 1.98-12.78)。体外实验显示 TNFR2-R 细胞在无 TNFα 刺激时促炎基因表达更高(P < .01),该活性不被 TNFα 中和抗体影响,但可被 ROCK 特异性抑制剂阻断。
要点
- TNFR2-R 变异携带者因疗效不足 12 个月内停用 TNFi 的可能性约为 TNFR2-M 携带者的 5 倍(95% CI 1.98-12.78)。
- TNFR2-R 细胞在无 TNFα 刺激时促炎基因表达高于 TNFR2-M 细胞(P < .01)。
- TNFR2-R 的活性不被 TNFα 中和抗体影响,但可被 ROCK 特异性抑制剂阻断。
核心结论
- TNFR2 rs1061622 多态性显著影响银屑病关节炎患者对 TNFi 治疗的应答。
- TNFR2-R 变异赋予的不依赖 TNFα 但依赖 ROCK 活性的功能获得性活性,可能是部分患者 TNFi 应答不足的机制。
研究设计与样本
- 采用限制性片段长度多态性分析评估 164 例银屑病关节炎患者的 TNFR2 rs1061622 多态性状态。
- 主要结局为通过病历回顾确定的因疗效不足在 12 个月内停用 TNFi 药物。
- 使用表达内源性或重组 TNFR2-M 或 TNFR2-R 的人内皮细胞及表达重组 TNFR2-M 或 TNFR2-R 的 Jurkat T 细胞研究细胞信号传导和基因表达差异。
主要发现
- 携带 TNFR2-R 变异的银屑病关节炎患者因疗效不足在 12 个月内停用 TNFi 的可能性约为 TNFR2-M 携带者的 5 倍(95% CI 1.98-12.78)。
- 携带 TNFR2-R 等位基因的细胞在无 TNFα 刺激时促炎基因表达水平更高(P < .01)。
- TNFR2-R 的上述活性不被 TNFα 中和抗体影响,但可被 ROCK 特异性抑制剂阻断。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Front-line treatment for psoriatic arthritis (PsA) often involves the use of tumour necrosis factor alpha (TNFα) blocking medications (tumour necrosis factor alpha inhibition [TNFi]). However, more than 40% of patients exhibit inadequate responses, and there is no predictive clinical test available. Our goal is to investigate whether the response to TNFi treatment is associated with TNFα receptor 2 (TNFR2) rs1061622 polymorphic variants, TNFR2-M or TNFR2-R, in PsA. Furthermore, to elucidate the underlying mechanisms, differences in cell signalling and gene expression conferred by TNFR2-M vs TNFR2-R were examined. METHODS: TNFR2 rs1061622 polymorphism status of 164 patients was assessed using restriction fragment length polymorphisms analysis. Discontinuation of the TNFi agents <12 months due to inadequate efficacy determined by chart review was the primary outcome. Human endothelial cells expressing endogenous or recombinant TNFR2-M or TNFR2-R and Jurkat T cells expressing recombinant TNFR2-M or TNFR2-R were utilised to investigate differences in cell signalling and gene expression. RESULTS: Patients with PsA with TNFR2-R variant had a ∼5-fold increased likelihood of discontinuing TNFi therapy <12 months, vs TNFR2-M carriers (95% CI 1.98-12.78). The cells with TNFR2-R alleles showed higher levels of proinflammatory gene expression in the absence of TNFa stimulation (P < .01). This activity of TNFR2-R was unaffected by a TNFα-neutralising antibody, whereas blocked by a Rho kinase (ROCK)-specific inhibitor. CONCLUSIONS: TNFR2 rs1061622 polymorphism significantly influences TNFi therapy responsiveness in PsA. The TNFα-independent, but ROCK activity-dependent gain-of-function activity conferred by TNFR2-R variant potentially serves as a mechanism underlying inadequate responses to TNFi in a subset of patients with PsA.
引用
- Sullivan JK, Rai V, Harvey J, et al. Inadequate response to anti-TNFα therapy is associated with a gain-of-function TNFR2-R polymorphic variant in patients with psoriatic arthritis. Ann Rheum Dis. 2025. PMID: 41206243. doi:10.1016/j.ard.2025.10.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。